X
X

Dr. Basavaraj H

   MBBS, DMRT, DNB (Radiotherapy)

Book An Appointment

Home / Doctors / Dr. Basavaraj H

Dr. Basavaraj H

  Qualification

MBBS, DMRT, DNB (Radiotherapy)

  Specialities

Radiation Oncology

  Locations

HCG NMR Cancer Centre - Hubli

  Experience

5 Years

Introduction
Expertise
  • Dr. Basavaraj's expertise lies in clinical radiation oncology and advanced technology conventional planning and delivering radiation therapy through various techniques, such as 3DCRT, IMRT/IGRT, RapidArc, SRS and SBRT.          
  • He also has hands-on experience in advanced brachytherapy procedures – intracavitary brachytherapy (ICBT) /interstitial brachytherapy (ISBT) and intraluminal brachytherapy for cancers of esophagus, head and neck region, sarcoma and gynaecological malignancies, namely cervical and endometrial cancers.
  • Dr. Basavaraj has handled over 3500 cases so far.
Recognition
  • Dr. Basavaraj has attended numerous events where he has presented his papers and posters and bagged multiple awards:
    • Presented a poster “Incidence of Vaginal Adhesion in Patients Treated with Radical Radiotherapy in Carcinoma Cervix” December 2013 held in Goa -GOKARNA.
    • Presented a paper “Incidence of Laryngeal Edema in Head and Neck Cancer Patient Treated with Concurrent Chemoradiation.” AROICON Delhi-2013
    • Carcinoma oesophagus with Clivus metastasis Case series. HCG Oncology Mirror April 2017
    • Incidence of primary hypothyroidism in patients exposed to therapeutic external beam radiation, where radiation portals include a part or whole of the thyroid gland (Free paper) AROICON Bangalore 2018
    • Presented a Paper “Prospective comparative analysis of Dysphagia in Standard IMRT vs.
    • Dysphagia Aspiration Related Structure Sparing IMRT in Head and Neck Cancer. ICC Bangalore
    • He is a member of numerous associations, such as the Indian Medical Association, Association of Radiation Oncologist of India, Indian College of Radiation Oncology and Indian Brachytherapy Society.
  • He has served as an investigator and principal investigator for many clinical trials and below are a few:
    • Unresectable EGFR mutation-positive Non-Small Cell Lung Cancer (Stage III) whose disease has not progressed following definitive platinum-based chemoradiation therapy (LAURA) (Principal investigator – Ongoing 2018)
    • Efficacy and safety of Intas Denosumab in comparison with Xgeva in patients with solid tumours with bone metastasis (Co-Investigator)

   Practices at

Other Doctors

HCG Call Icon